Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more
Sam Chun Dang Pharm. Co. Ltd (000250) - Total Liabilities
Latest total liabilities as of September 2025: ₩174.97 Billion KRW
Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has total liabilities worth ₩174.97 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sam Chun Dang Pharm. Co. Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sam Chun Dang Pharm. Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Silan Microelectronics Co Ltd
SHG:600460
|
China | CN¥12.33 Billion |
|
Sodexo SA
PA:SW
|
France | €11.05 Billion |
|
Swissquote Group Holding Ltd
PINK:SWQGF
|
USA | $13.21 Billion |
|
Wan Hai Lines Ltd
TW:2615
|
Taiwan | NT$137.41 Billion |
|
Great-West Lifeco Inc 4.50% Non-Cum 1st Pfd Shs Ser I
PINK:GRWTF
|
USA | $829.83 Billion |
|
Globalstar Inc
NYSE MKT:GSAT
|
USA | $523.47 Million |
|
Lifco AB (publ)
PINK:LFCBY
|
USA | $21.83 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Sam Chun Dang Pharm. Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sam Chun Dang Pharm. Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sam Chun Dang Pharm. Co. Ltd (2012–2024)
The table below shows the annual total liabilities of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩253.67 Billion | +131.53% |
| 2023-12-31 | ₩109.56 Billion | -44.96% |
| 2022-12-31 | ₩199.05 Billion | +15.79% |
| 2021-12-31 | ₩171.90 Billion | +31.77% |
| 2020-12-31 | ₩130.45 Billion | -1.38% |
| 2019-12-31 | ₩132.28 Billion | +17.43% |
| 2018-12-31 | ₩112.64 Billion | +26.84% |
| 2017-12-31 | ₩88.80 Billion | +11.08% |
| 2016-12-31 | ₩79.95 Billion | +14.30% |
| 2015-12-31 | ₩69.94 Billion | +113.15% |
| 2014-12-31 | ₩32.81 Billion | -9.22% |
| 2013-12-31 | ₩36.15 Billion | +1.98% |
| 2012-12-31 | ₩35.44 Billion | -- |